Absci to Report Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results on March 24, 2026

Absci (Nasdaq: ABSI) will report business updates and fourth-quarter and full-year 2025 financial and operating results after market close on March 24, 2026.

Rhea-AI Summary

Absci (Nasdaq: ABSI) will report business updates and fourth-quarter and full-year 2025 financial and operating results after market close on March 24, 2026.

A webcast and live audio conference call will begin at 4:30 p.m. ET (1:30 p.m. PT), with the live stream and archived replay available via the company’s investor relations site at investors.absci.com.

Argus Feb 24 session

+2.26% close to close Open Argus

Details

News Market Reaction – ABSI

On Feb 24, the day this news came out, ABSI closed 2.26% above the previous close.

Data tracked by StockTitan Argus for the Feb 24 session.

Key Figures

Shelf registration size: $400,000,000 ATM capacity: $100,000,000 Q3 2025 partner revenue: $0.378 million +5 more

Shelf registration size

$400,000,000

Total securities under Form S-3 shelf filed 2025-08-12

ATM capacity

$100,000,000

Common stock under sales agreement with TD Securities

Q3 2025 partner revenue

$0.378 million

Quarter ended September 30, 2025

Q3 2025 net loss

$28.7 million

Quarter ended September 30, 2025

Cash & securities

$152.5 million

Balance as of September 30, 2025

Shares outstanding

150,371,531

As of October 31, 2025

HEADLINE trial size

Up to 227 participants

Phase 1/2a ABS-201 trial design

52-week range

$2.01–$5.41

Pre-announcement trading range

Historical Context

5 past events · Latest: Feb 17

5 events

1. Feb 17

   Investor conferences

   24h Move

   +4.3%

   Planned participation in several March 2026 investor conferences and webcasts.

2. Dec 16

   Major conference

   24h Move

   +4.7%

   Presentation and webcast at the 44th Annual J.P. Morgan Healthcare Conference.

3. Dec 11

   Clinical data update

   24h Move

   -3.3%

   New human ex vivo data on ABS-201 suggesting potential reversal of follicle miniaturization.

4. Dec 10

   Patient advocacy deal

   24h Move

   +12.8%

   Partnership with Landon Donovan to elevate patient voice in hair-loss research for ABS-201.

5. Dec 04

   Trial initiation

   24h Move

   +11.7%

   First participants dosed in Phase 1/2a HEADLINE trial of AI-designed antibody ABS-201.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

generative ai, webcast

2 terms

generative ai technical

"advancing breakthrough therapeutics designed with generative AI, today announced the company"

Generative AI is a type of computer technology that can create new content, like text, images, or music, on its own. It’s important because it can produce realistic and useful material quickly, which could change how we create art, write stories, or even develop new products. Think of it as a smart robot that can invent and produce things almost like a human.

webcast technical

"Absci management will webcast a corresponding conference call beginning at 4:30 p.m."

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

VANCOUVER, Wash. and NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the fourth quarter and full year 2025 after market close on Tuesday, March 24, 2026.

Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook.

Live audio of the webcast will be available on the company’s investor relations website at: investors.absci.com. The webcast will be archived and available for replay after the event.

About Absci

Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Our Integrated Drug Creation™ platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. Absci’s approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Each cycle refines our data and strengthens our models, facilitating rapid innovation and enhancing the precision of our therapeutic designs. Alongside collaborations with top pharmaceutical, biotech, tech, and academic leaders, Absci is advancing its own pipeline of AI designed therapeutics including ABS-201™, a groundbreaking innovation in hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern hair-loss. ABS-201 is also being investigated as a potential “best-in-class” therapeutic for endometriosis, a condition with significant unmet medical need and market potential. Absci is headquartered in Vancouver, WA, with AI Research Labs in New York City and Serbia, and an Innovation Center in Switzerland. Learn more at www.absci.com or follow us on LinkedIn (@absci), X (@Abscibio) and YouTube.

Absci® standard character mark, ABS-201™, and Integrated Drug Creation™ are trademarks and registered trademarks of Absci Corporation.

Investor Contact
Alexander D.H. Khan
Corporate Vice President, Head of Investor Relations
investors@absci.com

Media Contact
press@absci.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Absci (ABSI) report Q4 and full-year 2025 results?

Absci will report Q4 and full-year 2025 results after market close on March 24, 2026. According to the company, management will release business updates and financial and operating results and discuss outlook during the webcasted conference call that same day.

What time is the Absci (ABSI) earnings conference call on March 24, 2026?

The Absci conference call begins at 4:30 p.m. Eastern Time on March 24, 2026. According to the company, the call will follow the results release and include management discussion of business developments, financial results, and outlook.

Where can investors access the Absci (ABSI) webcast and replay?

Investors can access the live webcast and archived replay on Absci’s investor relations website at investors.absci.com. According to the company, live audio will stream during the call and the webcast will be archived for later replay.

Will Absci (ABSI) discuss business developments during the March 24, 2026 call?

Yes. Absci management will discuss business developments during the March 24, 2026 call and webcast. According to the company, the session will cover recent operating progress, financial results for Q4 and full-year 2025, and the company’s outlook.

How can shareholders prepare to follow Absci’s (ABSI) March 24, 2026 results release?

Shareholders should plan to join the webcast at 4:30 p.m. ET and review the company’s published materials after the release. According to the company, the webcast will be available live and archived on the investor relations website for later review.